While androgen deprivation therapy (ADT) remains the mainstay of systemic treatment, the addition of AR signaling inhibitors (ARSIs) provides substantial improvement in overall survival and quality of life for many men with advanced prostate cancer [1,2,3,4,5,6,7]. This evidence concerns the gene AR and Familial prostate cancer.